CoChat

The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study

Open access
Gillett, Mike, Brennan, Alan, Watson, Penny, Khunti, Kamlesh, Davies, Melanie, Mostafa, Samiul, Gray, Laura J · 2015 · Health Technology Assessment
Cited by 36

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: An estimated 850,000 people have diabetes without knowing it and as many as 7 million more are at high risk of developing it. Within the NHS Health Checks programme, blood glucose testing can be undertaken using a fasting plasma glucose (FPG) or a glycated haemoglobin (HbA 1c) test but the relative cost-effectiveness of these is unknown. Objectives: To estimate and compare the cost-effectiveness of screening for type 2 diabetes using a HbA 1c test versus a FPG test. In addition, to compare the use of a random capillary glucose (RCG) test versus a non-invasive risk score to prioritise individuals who should undertake a HbA 1c or FPG test. Design: Cost-effectiveness analysis using the Sheffield Type 2 Diabetes Model to model lifetime incidence of complications, costs and health benefits of screening. Setting: England; population in the 40–74-years age range eligible for a NHS health check. Data sources: The Leicester Ethnic Atherosclerosis and Diabetes Risk (LEADER) data set was used to analyse prevalence and screening outcomes for a multiethnic population. Alternative prevalence rates were obtained from the literature or through personal communication. Methods: (1) Modelling of screening pathways to determine the cost per case detected followed by long-term modelling of glucose progression and complications associated with hyperglycaemia; and (2) calculation of the costs and health-related quality of life arising from complications and calculation of overall cost per quality-adjusted life-year (QALY), net monetary benefit and the likelihood of cost-effectiveness. Results: Based on the LEADER data set from a multiethnic population, the results indicate that screening using a HbA 1c test is more cost-effective than using a FPG. For National Institute for Health and Care Excellence (NICE)-recommended screening strategies, HbA 1c leads to a cost saving of £12 and a QALY gain of 0.0220 per person when a risk score is used as a prescreen. With no prescreen, the cost saving is £30 with a QALY gain of 0.0224. Probabilistic sensitivity analysis indicates that the likelihood of HbA 1c being more cost-effective than FPG is 98% and 95% with and without a risk score, respectively. One-way sensitivity analyses indicate that the results based on prevalence in the LEADER data set are insensitive to a variety of alternative assumptions. However, where a region of the country has a very different joint HbA 1c and FPG distribution from the LEADER data set such that a FPG test yields a much higher prevalence of high-risk cases relative to HbA 1c, FPG may be more cost-effective. The degree to which the FPG-based prevalence would have to be higher depends very much on the uncertain relative uptake rates of the two tests. Using a risk score such as the Leicester Practice Database Score (LPDS) appears to be more cost-effective than using a RCG test to identify individuals with the highest risk of diabetes who should undergo blood testing. Limitations: We did not include rescreening because there was an absence of required relevant evidence. Conclusions: Based on the multiethnic LEADER population, among individuals currently attending NHS Health Checks, it is more cost-effective to screen for diabetes using a HbA 1c test than using a FPG test. However, in some localities, the prevalence of diabetes and high risk of diabetes may be higher for FPG relative to HbA 1c than in the LEADER cohort. In such cases, whether or not it still holds that HbA 1c is likely to be more cost-effective than FPG depends on the relative uptake rates for HbA 1c and FPG. Use of the LPDS appears to be more cost-effective than a RCG test for prescreening. Funding: The National Institute for Health Research Health Technology Assessment programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta19330

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 36

Metadata

Authors
Gillett, M., Brennan, A., Watson, P., Khunti, K., Davies, M., Mostafa, S., & Gray, L. J.
Venue
Health Technology Assessment
Published
2015-05
Volume
19
Issue
33
Pages
1-80
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W640011566
Cited by
36
References
16
FWCI
11.21
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. https://app.cochat.ai/papers/10.3310/hta19330
The paper
Gillett, M., Brennan, A., Watson, P., Khunti, K., Davies, M., Mostafa, S., & Gray, L. J. (2015). The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment. https://doi.org/10.3310/hta19330

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.